Persistence of DNMT3A mutations at long-term remission in adult patients with AML

British Journal of Haematology

Volumn 167, Issue 4, 2014, Pages 478-486

  Pløen, Gro G ^a   Nederby, Line ^a   Guldberg, Per ^b   Hansen, Maria ^a   Ebbesen, Lene H ^a   Jensen, Uffe Birk ^a   Hokland, Peter ^a   Aggerholm, Anni ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

DNMT3A; Acute myeloid leukaemia; Mutation; Pre leukaemic; Remission

Indexed keywords

CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; DNA; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; NUCLEOPHOSMIN; DNA (CYTOSINE 5) METHYLTRANSFERASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; BLAST CELL; CONTROLLED STUDY; DNMT3A GENE; DRUG MEGADOSE; FEMALE; FLT3 GENE; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; IDH1 GENE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUTANT; MYELODYSPLASTIC SYNDROME; NPM1 GENE; PRIORITY JOURNAL; T LYMPHOCYTE; ADOLESCENT; ALLELE; CLINICAL TRIAL; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MUTATION; PATHOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; B-LYMPHOCYTES; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE FREQUENCY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; T-LYMPHOCYTES;

EID: 84916229685     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13062     Document Type: Article

References (33)

1. Aggerholm, A., Holm, M.S., Guldberg, P., Olesen, L.H. & Hokland, P. (2006) Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. European Journal of Haematology, 76, 23-32.
2. Cancer Genome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The New England Journal of Medicine, 368, 2059-2074.
3. Corces-Zimmerman, M.R., Hong, W.J., Weissman, I.L., Medeiros, B.C. & Majeti, R. (2014) Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proceedings of the National Academy of Sciences of the United States of America, 111, 2548-2553.
4. Dohner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Buchner, T., Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R.A., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M.A., Sierra, J., Tallman, M.S., Lowenberg, B., Bloomfield, C.D. & European LeukemiaNet. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the european LeukemiaNet. Blood, 115, 453-474.
5. Estey, E. & Dohner, H. (2006) Acute myeloid leukaemia. Lancet, 368, 1894-1907.
6. Fathi, A.T. & Abdel-Wahab, O. (2012) Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Advances in Hematology, 2012, 469592.
7. Gaidzik, V.I., Schlenk, R.F., Paschka, P., Stolzle, A., Spath, D., Kuendgen, A., von Lilienfeld-Toal, M., Brugger, W., Derigs, H.G., Kremers, S., Greil, R., Raghavachar, A., Ringhoffer, M., Salih, H.R., Wattad, M., Kirchen, H.G., Runde, V., Heil, G., Petzer, A.L., Girschikofsky, M., Heuser, M., Kayser, S., Goehring, G., Teleanu, M.V., Schlegelberger, B., Ganser, A., Krauter, J., Bullinger, L., Dohner, H. & Dohner, K. (2013) Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML study group (AMLSG). Blood, 121, 4769-4777.
8. Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J., Burnett, A.K. & National Cancer Research Institute Adult Leukaemia Working Group. (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the united kingdom medical research council trials. Blood, 116, 354-365.
9. Hokland, P. & Ommen, H.B. (2011) Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood, 117, 2577-2584.
10. Hou, H.A., Kuo, Y.Y., Liu, C.Y., Chou, W.C., Lee, M.C., Chen, C.Y., Lin, L.I., Tseng, M.H., Huang, C.F., Chiang, Y.C., Lee, F.Y., Liu, M.C., Liu, C.W., Tang, J.L., Yao, M., Huang, S.Y., Ko, B.S., Hsu, S.C., Wu, S.J., Tsay, W., Chen, Y.C. & Tien, H.F. (2012) DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood, 119, 559-568.
11. Jan, M., Snyder, T.M., Corces-Zimmerman, M.R., Vyas, P., Weissman, I.L., Quake, S.R. & Majeti, R. (2012) Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Science Translational Medicine, 4, 149ra118.
12. Kihara, R., Nagata, Y., Kiyoi, H., Kato, T., Yamamoto, E., Suzuki, K., Chen, F., Asou, N., Ohtake, S., Miyawaki, S., Miyazaki, Y., Sakura, T., Ozawa, Y., Usui, N., Kanamori, H., Kiguchi, T., Imai, K., Uike, N., Kimura, F., Kitamura, K., Nakaseko, C., Onizuka, M., Takeshita, A., Ishida, F., Suzushima, H., Kato, Y., Miwa, H., Shiraishi, Y., Chiba, K., Tanaka, H., Miyano, S., Ogawa, S. & Naoe, T. (2014) Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia, doi: 10.1038/leu.2014.55.
13. Kronke, J., Bullinger, L., Teleanu, V., Tschurtz, F., Gaidzik, V.I., Kuhn, M.W., Rucker, F.G., Holzmann, K., Paschka, P., Kapp-Schworer, S., Spath, D., Kindler, T., Schittenhelm, M., Krauter, J., Ganser, A., Gohring, G., Schlegelberger, B., Schlenk, R.F., Dohner, H. & Dohner, K. (2013) Clonal evolution in relapsed NPM1 mutated acute myeloid leukemia. Blood, 122, 100-108.
14. LaRochelle, O., Bertoli, S., Vergez, F., Sarry, J.E., Mansat-De Mas, V., Dobbelstein, S., Dastugue, N., Strzelecki, A.C., Cavelier, C., Creancier, L., Pillon, A., Kruczynski, A., Demur, C., Sarry, A., Huguet, F., Huynh, A., Recher, C. & Delabesse, E. (2011) Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget, 2, 850-861.
15. Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Larson, D.E., Kandoth, C., Payton, J.E., Baty, J., Welch, J., Harris, C.C., Lichti, C.F., Townsend, R.R., Fulton, R.S., Dooling, D.J., Koboldt, D.C., Schmidt, H., Zhang, Q., Osborne, J.R., Lin, L., O'Laughlin, M., McMichael, J.F., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Magrini, V.J., Vickery, T.L., Hundal, J., Cook, L.L., Conyers, J.J., Swift, G.W., Reed, J.P., Alldredge, P.A., Wylie, T., Walker, J., Kalicki, J., Watson, M.A., Heath, S., Shannon, W.D., Varghese, N., Nagarajan, R., Westervelt, P., Tomasson, M.H., Link, D.C., Graubert, T.A., DiPersio, J.F., Mardis, E.R. & Wilson, R.K. (2010) DNMT3A mutations in acute myeloid leukemia. The New England Journal of Medicine, 363, 2424-2433.
16. Marcucci, G., Metzeler, K.H., Schwind, S., Becker, H., Maharry, K., Mrozek, K., Radmacher, M.D., Kohlschmidt, J., Nicolet, D., Whitman, S.P., Wu, Y.Z., Powell, B.L., Carter, T.H., Kolitz, J.E., Wetzler, M., Carroll, A.J., Baer, M.R., Moore, J.O., Caligiuri, M.A., Larson, R.A. & Bloomfield, C.D. (2012) Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30, 742-750.
17. Marcucci, G., Yan, P., Maharry, K., Frankhouser, D., Nicolet, D., Metzeler, K.H., Kohlschmidt, J., Mrozek, K., Wu, Y.Z., Bucci, D., Curfman, J.P., Whitman, S.P., Eisfeld, A.K., Mendler, J.H., Schwind, S., Becker, H., Bar, C., Carroll, A.J., Baer, M.R., Wetzler, M., Carter, T.H., Powell, B.L., Kolitz, J.E., Byrd, J.C., Plass, C., Garzon, R., Caligiuri, M.A., Stone, R.M., Volinia, S., Bundschuh, R. & Bloomfield, C.D. (2014) Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 32, 548-556.
18. Meloni, G., Mancini, M., Gianfelici, V., Martelli, M.P., Foa, R. & Falini, B. (2009) Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability. Haematologica, 94, 298-300.
19. Metzeler, K.H., Walker, A., Geyer, S., Garzon, R., Klisovic, R.B., Bloomfield, C.D., Blum, W. & Marcucci, G. (2012) DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia, 26, 1106-1107.
20. Mrozek, K., Heerema, N.A. & Bloomfield, C.D. (2004) Cytogenetics in acute leukemia. Blood Reviews, 18, 115-136.
21. Mrozek, K., Marcucci, G., Paschka, P., Whitman, S.P. & Bloomfield, C.D. (2007) Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood, 109, 431-448.
22. Ommen, H.B., Schnittger, S., Jovanovic, J.V., Ommen, I.B., Hasle, H., Ostergaard, M., Grimwade, D. & Hokland, P. (2010) Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood, 115, 198-205.
23. Paschka, P., Marcucci, G., Ruppert, A.S., Whitman, S.P., Mrozek, K., Maharry, K., Langer, C., Baldus, C.D., Zhao, W., Powell, B.L., Baer, M.R., Carroll, A.J., Caligiuri, M.A., Kolitz, J.E., Larson, R.A. & Bloomfield, C.D. (2008) Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26, 4595-4602.
24. Paschka, P., Schlenk, R.F., Gaidzik, V.I., Habdank, M., Kronke, J., Bullinger, L., Spath, D., Kayser, S., Zucknick, M., Gotze, K., Horst, H.A., Germing, U., Dohner, H. & Dohner, K. (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 3636-3643.
25. Patel, J.P., Gonen, M., Figueroa, M.E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., Huberman, K., Cheng, J., Viale, A., Socci, N.D., Heguy, A., Cherry, A., Vance, G., Higgins, R.R., Ketterling, R.P., Gallagher, R.E., Litzow, M., van den Brink, M.R., Lazarus, H.M., Rowe, J.M., Luger, S., Ferrando, A., Paietta, E., Tallman, M.S., Melnick, A., Abdel-Wahab, O. & Levine, R.L. (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. The New England Journal of Medicine, 366, 1079-1089.
26. Renneville, A., Boissel, N., Nibourel, O., Berthon, C., Helevaut, N., Gardin, C., Cayuela, J.M., Hayette, S., Reman, O., Contentin, N., Bordessoule, D., Pautas, C., Botton, S., Revel, T., Terre, C., Fenaux, P., Thomas, X., Castaigne, S., Dombret, H. & Preudhomme, C. (2012) Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the acute leukemia french association. Leukemia, 26, 1247-1254.
27. Ribeiro, A.F., Pratcorona, M., Erpelinck-Verschueren, C., Rockova, V., Sanders, M., Abbas, S., Figueroa, M.E., Zeilemaker, A., Melnick, A., Lowenberg, B., Valk, P.J. & Delwel, R. (2012) Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood, 119, 5824-5831.
28. Roug, A.S., Larsen, H.O., Nederby, L., Just, T., Brown, G., Nyvold, C.G., Ommen, H.B. & Hokland, P. (2014) hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia. British Journal of Haematology, 164, 212-222.
29. Schlenk, R.F., Dohner, K., Krauter, J., Frohling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Spath, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A., Dohner, H. & German-Austrian Acute Myeloid Leukemia Study Group. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. The New England Journal of Medicine, 358, 1909-1918.
30. Shlush, L.I., Zandi, S., Mitchell, A., Chen, W.C., Brandwein, J.M., Gupta, V., Kennedy, J.A., Schimmer, A.D., Schuh, A.C., Yee, K.W., McLeod, J.L., Doedens, M., Medeiros, J.J., Marke, R., Kim, H.J., Lee, K., McPherson, J.D. & Hudson, T.J., HALT Pan-Leukemia Gene Panel Consortium, Brown, A.M., Trinh, Q.M., Stein, L.D., Minden, M.D., Wang, J.C. & Dick, J.E. (2014) Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature, 506, 328-333.
31. Silkjaer, T., Norgaard, J.M., Aggerholm, A., Ebbesen, L.H., Kjeldsen, E., Hokland, P. & Nyvold, C.G. (2013) Characterization and prognostic significance of mitochondrial DNA variations in acute myeloid leukemia. European Journal of Haematology, 90, 385-396.
32. Thol, F., Damm, F., Ludeking, A., Winschel, C., Wagner, K., Morgan, M., Yun, H., Gohring, G., Schlegelberger, B., Hoelzer, D., Lubbert, M., Kanz, L., Fiedler, W., Kirchner, H., Heil, G., Krauter, J., Ganser, A. & Heuser, M. (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 2889-2896.
33. Yan, X.J., Xu, J., Gu, Z.H., Pan, C.M., Lu, G., Shen, Y., Shi, J.Y., Zhu, Y.M., Tang, L., Zhang, X.W., Liang, W.X., Mi, J.Q., Song, H.D., Li, K.Q., Chen, Z. & Chen, S.J. (2011) Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nature Genetics, 43, 309-315.